Salute e Benessere
Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure
The study presents the long-term follow-up of patients enrolled in the initial pilot trial of the , designed to restore myocardial function in patients with chronic heart failure. This publication marks the first report of sustained clinical benefit following the discontinuation of active therapy—two years after initial device implantation.
The two-year follow-up evaluated the safety, durability, and efficacy of C-MIC therapy in seven patients with chronic heart failure (NYHA Class III, mean LVEF 31.7%). Patients who had completed the initial six-month pilot trial were reassessed for mortality, hospitalization rates, device-related adverse events, and functional status.
Key findings include:
"These findings offer important clinical insights into the long-term potential of C-MIC therapy," said , the study's first author and Co-Principal Investigator. "What's most encouraging is that the improvements in cardiac function and patient well-being were sustained even after the device was deactivated, suggesting a disease-modifying effect."
, CEO of Berlin Heals, added: "The publication of this study reinforces our confidence in microcurrent therapy as a transformative treatment for heart failure. These two-year results validate both the safety and long-lasting impact of C-MIC and set the stage for larger clinical trials."
Berlin Heals is currently expanding its clinical development program, with the multicenter trial now underway in several European countries.
To access the full publication in , please visit http://doi.org/10.1002/ehf2.15369.
John Brumfield
media@berlinheals.de
Logo: https://mma.prnewswire.com/media/2622179/5412887/Berlin_Heals_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/berlin-heals-announces-publication-of-two-year-clinical-outcomes-of-cardiac-microcurrent-therapy-in-esc-heart-failure-302504559.html